Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment
The incidence of thyroid cancer has been rising in recent years. While tumorigenesis has traditionally been attributed to the accumulation of genetic mutations in oncogenes and tumor suppressor genes, increasing attention has been directed toward the role of epigenetic regulation in cancer developme...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1549477/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849326653000384512 |
|---|---|
| author | Yanmei Han Yanmei Han Yanmei Han Bian Wu Jie Tan Ruolin Wu Ruolin Wu Ruolin Wu Jingjing Wang Jingjing Wang Jingjing Wang Xiaojing Ren Xiaojing Ren Xiaojing Ren Yajing Zhang Yajing Zhang Yajing Zhang Zairong Gao Zairong Gao Zairong Gao Xiaotian Xia Xiaotian Xia Xiaotian Xia |
| author_facet | Yanmei Han Yanmei Han Yanmei Han Bian Wu Jie Tan Ruolin Wu Ruolin Wu Ruolin Wu Jingjing Wang Jingjing Wang Jingjing Wang Xiaojing Ren Xiaojing Ren Xiaojing Ren Yajing Zhang Yajing Zhang Yajing Zhang Zairong Gao Zairong Gao Zairong Gao Xiaotian Xia Xiaotian Xia Xiaotian Xia |
| author_sort | Yanmei Han |
| collection | DOAJ |
| description | The incidence of thyroid cancer has been rising in recent years. While tumorigenesis has traditionally been attributed to the accumulation of genetic mutations in oncogenes and tumor suppressor genes, increasing attention has been directed toward the role of epigenetic regulation in cancer development. Since the 1980s, however, it has been acknowledged that the role of another key regulatory system in carcinogenesis: epigenetics, shedding light on the regulation of gene expression without altering the DNA sequence.This review synthesizes current literature on epigenetic alterations in follicular cell-derived thyroid cancers, focusing on DNA methylation, histone modifications, chromatin remodeling, and RNA regulation. Evidence indicates that dysregulation of these epigenetic processes is prevalent in thyroid cancer, influencing tumor initiation, progression, and resistance to therapy. Several epigenetic inhibitors are under development, some demonstrating synergy with existing chemotherapies and immunotherapies. Understanding these mechanisms may facilitate the development of novel, more effective strategies for early detection and treatment. |
| format | Article |
| id | doaj-art-ee669c8dbdfa43d18a8dd5bc75cc16c8 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ee669c8dbdfa43d18a8dd5bc75cc16c82025-08-20T03:48:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15494771549477Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatmentYanmei Han0Yanmei Han1Yanmei Han2Bian Wu3Jie Tan4Ruolin Wu5Ruolin Wu6Ruolin Wu7Jingjing Wang8Jingjing Wang9Jingjing Wang10Xiaojing Ren11Xiaojing Ren12Xiaojing Ren13Yajing Zhang14Yajing Zhang15Yajing Zhang16Zairong Gao17Zairong Gao18Zairong Gao19Xiaotian Xia20Xiaotian Xia21Xiaotian Xia22Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, ChinaThe incidence of thyroid cancer has been rising in recent years. While tumorigenesis has traditionally been attributed to the accumulation of genetic mutations in oncogenes and tumor suppressor genes, increasing attention has been directed toward the role of epigenetic regulation in cancer development. Since the 1980s, however, it has been acknowledged that the role of another key regulatory system in carcinogenesis: epigenetics, shedding light on the regulation of gene expression without altering the DNA sequence.This review synthesizes current literature on epigenetic alterations in follicular cell-derived thyroid cancers, focusing on DNA methylation, histone modifications, chromatin remodeling, and RNA regulation. Evidence indicates that dysregulation of these epigenetic processes is prevalent in thyroid cancer, influencing tumor initiation, progression, and resistance to therapy. Several epigenetic inhibitors are under development, some demonstrating synergy with existing chemotherapies and immunotherapies. Understanding these mechanisms may facilitate the development of novel, more effective strategies for early detection and treatment.https://www.frontiersin.org/articles/10.3389/fonc.2025.1549477/fullepigeneticsfollicular cell-derived thyroid cancerbiomarkersinhibitorstherapy |
| spellingShingle | Yanmei Han Yanmei Han Yanmei Han Bian Wu Jie Tan Ruolin Wu Ruolin Wu Ruolin Wu Jingjing Wang Jingjing Wang Jingjing Wang Xiaojing Ren Xiaojing Ren Xiaojing Ren Yajing Zhang Yajing Zhang Yajing Zhang Zairong Gao Zairong Gao Zairong Gao Xiaotian Xia Xiaotian Xia Xiaotian Xia Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment Frontiers in Oncology epigenetics follicular cell-derived thyroid cancer biomarkers inhibitors therapy |
| title | Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment |
| title_full | Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment |
| title_fullStr | Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment |
| title_full_unstemmed | Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment |
| title_short | Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment |
| title_sort | epigenetic modifications in follicular cell derived thyroid cancer new dimensions in pathogenesis and treatment |
| topic | epigenetics follicular cell-derived thyroid cancer biomarkers inhibitors therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1549477/full |
| work_keys_str_mv | AT yanmeihan epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT yanmeihan epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT yanmeihan epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT bianwu epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT jietan epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT ruolinwu epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT ruolinwu epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT ruolinwu epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT jingjingwang epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT jingjingwang epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT jingjingwang epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT xiaojingren epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT xiaojingren epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT xiaojingren epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT yajingzhang epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT yajingzhang epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT yajingzhang epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT zaironggao epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT zaironggao epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT zaironggao epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT xiaotianxia epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT xiaotianxia epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment AT xiaotianxia epigeneticmodificationsinfollicularcellderivedthyroidcancernewdimensionsinpathogenesisandtreatment |